Finding a new treatment target for breast cancer in African American women
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women
This study is looking at why African American women are more affected by a specific type of breast cancer called triple negative breast cancer, and it aims to create new treatments that target a special protein found in their cancer cells to help fight the disease with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10873727 on NIH RePORTER |
What this research studies
This research investigates the biological factors contributing to breast cancer disparities in African American women, particularly focusing on triple negative breast cancer (TNBC). The team has identified a receptor called lipolysis-stimulated lipoprotein receptor (LSR) that is highly expressed in breast cancer cells from African American patients. They are developing targeted therapies using antibody-drug conjugates (ADCs) that specifically target LSR to inhibit tumor growth with minimal side effects. The study will analyze genetic and epigenetic differences in breast cancer tissues from African American and Caucasian American patients to better understand these disparities.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with triple negative breast cancer.
Not a fit: Patients who do not have breast cancer or those with non-triple negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for breast cancer in African American women, potentially improving survival rates.
How similar studies have performed: Similar research has shown promise in targeting specific biological factors in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Liu, Runhua Runa — University of Alabama at Birmingham
- Study coordinator: Liu, Runhua Runa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.